Clinical Trial Update: 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) [EARLY_Phase 1]

View source ↗

Summary

Early-phase study 64Cu-TLX592 evaluated safety, pharmacokinetics, biodistribution, and dosimetry in metastatic prostate cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 64Cu-TLX592

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Metastatic Prostate Cancer | EARLY_Phase 1 | Status: COMPLETED